Drug Profile
Prednisolone/zoledronic acid - Levolta Pharmaceuticals
Alternative Names: VOLT-01Latest Information Update: 16 Jun 2023
Price :
$50
*
At a glance
- Originator Levolta Pharmaceuticals
- Developer Levolta Pharmaceuticals; Menzies Research Institute Tasmania
- Class Anti-inflammatories; Bisphosphonates; Calcium regulators; Corticosteroids; Drug conjugates; Glucocorticoids; Imidazoles; Osteoporosis therapies; Pregnadienetriols; Small molecules
- Mechanism of Action Bone resorption factor inhibitors; Glucocorticoid receptor agonists; HMG-CoA reductase inhibitors; Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Osteoarthritis
Highest Development Phases
- Phase III Osteoarthritis
Most Recent Events
- 16 Jun 2023 Prednisolone/zoledronic acid - Levolta Pharmaceuticals is available for licensing as of 01 Jun 2023. https://www.levoltapharma.com/about-us/
- 01 Jun 2023 Phase-II/III clinical trials in Osteoarthritis (IV)
- 01 Jun 2023 Tabuk Pharmaceuticals in-licenses prednisolone/zoledronic acid from Levolta Pharmaceuticals